NASDAQ: CDXSCodexis Inc Stock
$2.13+0.02 (+0.95%)
Updated Apr 21, 2025
CDXS Price
$2.13
Fair Value Price
N/A
Market Cap
$176.44M
52 Week Low
$1.90
52 Week High
$6.08
P/E
-2.39x
P/B
2.64x
P/S
5.9x
PEG
N/A
Dividend Yield
N/A
Revenue
$59.35M
Earnings
-$65.28M
Gross Margin
72.6%
Operating Margin
-92.42%
Profit Margin
-110%
Debt to Equity
1.23
Operating Cash Flow
-$49M
Beta
1.92
Next Earnings
Jun 11, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CDXS Overview
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CDXS's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CDXS
Ranked#436 of 462
Ranked#436 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important CDXS news, forecast changes, insider trades & much more!
CDXS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CDXS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CDXS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CDXS is good value based on its book value relative to its share price (2.64x), compared to the US Biotechnology industry average (4.04x)
P/B vs Industry Valuation
CDXS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CDXS due diligence checks available for Premium users.
Valuation
CDXS fair value
Fair Value of CDXS stock based on Discounted Cash Flow (DCF)
Price
$2.13
Fair Value
-$3.08
Undervalued by
169.07%
CDXS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CDXS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.39x
Industry
-184.27x
Market
27.14x
CDXS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.64x
Industry
4.04x
CDXS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CDXS's financial health
Profit margin
Revenue
$21.5M
Net Income
-$10.4M
Profit Margin
-48.4%
CDXS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CDXS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$149.0M
Liabilities
$82.1M
Debt to equity
1.23
CDXS's short-term assets ($98.77M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CDXS's short-term assets ($98.77M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CDXS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CDXS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$16.5M
Investing
-$2.9M
Financing
$1.1M
CDXS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CDXS vs Biotech Stocks
Codexis Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.